NEUP Key Statistics, Chart & Performance
The current stock price of NEUP is 4.19 USD. In the past month the price decreased by -0.48%. In the past year, price increased by 30.94%.
NEUP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About NEUP
Company Profile
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Company Info
NEUPHORIA THERAPEUTICS INC
100 Summit Dr
Burlington MASSACHUSETTS US
Employees: 7
NEUPHORIA THERAPEUTICS INC / NEUP FAQ
What does NEUP do?
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
What is the stock price of NEUPHORIA THERAPEUTICS INC today?
The current stock price of NEUP is 4.19 USD. The price increased by 2.95% in the last trading session.
What is the dividend status of NEUPHORIA THERAPEUTICS INC?
NEUP does not pay a dividend.
What is the ChartMill technical and fundamental rating of NEUP stock?
NEUP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists NEUP stock?
NEUP stock is listed on the Nasdaq exchange.
What is the expected growth for NEUP stock?
The Revenue of NEUPHORIA THERAPEUTICS INC (NEUP) is expected to grow by 686792% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for NEUP stock?
You can find the ownership structure of NEUPHORIA THERAPEUTICS INC (NEUP) on the Ownership tab.
NEUP Technical Analysis
NEUP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NEUP. NEUP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NEUP Financial Highlights
Over the last trailing twelve months NEUP reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -130% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.29% | ||
| ROE | -1.95% | ||
| Debt/Equity | 0 |
NEUP Forecast & Estimates
9 analysts have analysed NEUP and the average price target is 9.96 USD. This implies a price increase of 137.76% is expected in the next year compared to the current price of 4.19.
For the next year, analysts expect an EPS growth of -104017.17% and a revenue growth 686792% for NEUP